RBC Capital on Moderna (MRNA): 'we remain cautious on MRNA's ability to break even in 2028'
Tweet Send to a Friend
RBC Capital analyst Luca Issi reiterated a Sector Perform rating and $25.00 price target on Moderna (NASDAQ: MRNA).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
